论文部分内容阅读
目的:探讨联合应用琥珀酸美托洛尔、沙库巴曲缬沙坦钠治疗慢性心力衰竭(CHF)的临床效果。方法:抽取2018年8月至2020年7月在太原市人民医院治疗的64例CHF患者，将其分为两组。对照组32例使用琥珀酸美托洛尔治疗，观察组32例在对照组的基础上联合沙库巴曲缬沙坦钠治疗。比较两组患者的超声心动图指标、实验室指标、运动耐量、临床疗效及药物不良反应(ADR)。结果:治疗后，观察组患者左室射血分数(LVEF)、左心室短轴缩短率(FS)大于对照组，左心室舒张末期内径(LVEDD)小于对照组(n P<0.05)，观察组患者N端B型脑钠肽(NT-pro BNP)、生长分化因子-15(GDF-15)水平低于对照组，6分钟行走试验(6MWT)大于对照组(n P<0.05)；观察组与对照组总有效率比较，差异有统计学意义(n P0.05)。n 结论:联合用药方案可获得更加理想的治疗效果，能够有效改善患者心功能，延缓心肌重构，提高运动耐量，安全性良好。“,”Objective:To analyze the clinical efficacy of metoprolol succinate combined with valsartan sodium sacubitril on patients with chronic heart failure (CHF).Methods:A total of 64 CHF patients treated in Taiyuan People’s Hospital from August 2018 to July 2020 were selected, and divided into two groups, 32 cases in the control group were treated with metoprolol succinate; 32 cases in the observation group were treated with sacubitril and valsartan sodium on the control group. The echocardiographic indexes, laboratory indexes, exercise tolerance, clinical efficacy and adverse drug reaction (ADR) of the two groups of patients were compared.Results:After treatment, the left ventricular ejection fraction (LVEF) and fractioning shortening (FS) of the observation group were significantly higher than those of the control group, and the left ventricular end-diastolic diameter (LVEDD) was significantly lower than the control group (n P<0.05). The level of N-terminal fragment of the BNP precursor (NT-pro BNP) and growth differentiation factor-15(GDF-15)of the observation group was significantly lower than that of the control group, and 6-minute walk test (6MWT) was significantly greater (n P<0.05); there was significant difference in the total effective rate between the observation group and the control group (n P0.05).n Conclusions:The combination regimen can obtain a more ideal therapeutic effect, can effectively improve the patient’s cardiac function, delay myocardial remodeling, improve exercise tolerance, and has good safety.